Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02142504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02142504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2014
Completion date
January 6, 2016
Enrollment
454 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

norovirus prevention